EDO-S101
Cat. No.：YN290041
| 产品名称: | EDO-S101 |
| CAS No.: | 1236199-60-2 |
| Chemical Name: | 5-[bis(2-chloroethyl)amino]-N-hydroxy-1-methyl-1H-benzimidazole-2-heptanamide |
| Synonyms: | Tinostamustine |
| 分子量: | 415.36 |
| 分子式: | C₁₉H₂₈Cl₂N₄O₂ |
| SMILES: | O=C(NO)CCCCCCC1=NC2=CC(N(CCCl)CCCl)=CC=C2N1C |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | EDO-S101 (Tinostamustine) 是HDAC的广谱抑制剂；抑制HDAC1，HDAC2和HDAC3的IC50值分别为 9 nM，9 nM 和 25 nM。 |
| IC50和靶点: | [{name:"HDAC6:6 nM (IC50)"},{name: "HDAC1:9 nM (IC50)"},{name: "HDAC2:9 nM (IC50)"},{name: "HDAC3:25 nM (IC50)"},{name: "HDAC10:72 nM (IC50)"},{name: "HDAC8:107 nM (IC50)"}] |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
Mehrling, T., and Chen, Y.The alkylating-HDAC inhibition fusion principle: Taking chemotherapy to the next level with the first in class molecule EDO-S101Anticancer Agents Med. Chem.16(1),20-28(2016)
López-Iglesias, A.A., Herrero, A.B., Chesi, M., et al.Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repairJ. Hematol. Oncol.10(1),127(2017)
